Akston Biosciences Corporation

Akston Biosciences Corporation is a leader in the field of insulin engineering. The company was founded in 2011 by the former SmartCells, Inc. team who developed the world’s first clinical glucose-responsive insulin (acquired by Merck & Co. in 2010). Combining its core expertise with modern biotechnology manufacturing techniques, Akston is developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health. To date the company has raised over $6.3M from private investors and NIH grants.